Protalix BioTherapeutics to Present in the H.C. Wainwright 22nd Annual Global Investment Virtual Conference
Protalix BioTherapeutics, Inc. (NYSE American: PLX) announced that its CEO, Dror Bashan, will present at the H.C. Wainwright 22nd Annual Global Investment Virtual Conference on September 15, 2020, at 12:00 PM ET. This virtual event runs from September 14-16, 2020. A live webcast of the presentation will be available on Protalix's website, with a replay accessible for at least 15 days afterward. Protalix specializes in recombinant therapeutic proteins through its ProCellEx® plant-based expression system, which has FDA-approved products including taliglucerase alfa.
- None.
- None.
CARMIEL, Israel, Sept. 8, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that Dror Bashan, the Company's President and Chief Executive Officer will present in the H.C. Wainwright 22nd Annual Global Investment Virtual Conference on Tuesday, September 15, 2020 at 12:00 PM, Eastern Time. The conference will be held virtually on September 14-16, 2020.
A live webcast of the presentation will be available at www.protalix.com on the event calendar page, https://tinyurl.com/y5l9u4gr. A replay of the presentation will be archived and available for at least 15 days following the presentation.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix was the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. Protalix's unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner.
Protalix's first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the FDA in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights.
Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: pegunigalsidase alfa, a modified version of the recombinant human α–Galactosidase–A protein for the proposed treatment of Fabry disease; OPRX–106, an orally-delivered anti-inflammatory treatment; alidornase alfa for the treatment of Cystic Fibrosis; and others. Protalix has partnered with Chiesi Farmaceutici S.p.A., both in the United States and outside the United States, for the development and commercialization of pegunigalsidase alfa.
Investor Contact
Chuck Padala, Managing Director
LifeSci Advisors
+1-646-627-8390
chuck@lifesciadvisors.com
View original content:http://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-present-in-the-hc-wainwright-22nd-annual-global-investment-virtual-conference-301125354.html
SOURCE Protalix BioTherapeutics, Inc.
FAQ
When will Protalix BioTherapeutics present at the H.C. Wainwright Conference?
What is the ticker symbol for Protalix BioTherapeutics?
Where can I watch the Protalix presentation live?
What is Protalix’s main focus in biopharmaceuticals?
What products has Protalix BioTherapeutics developed?
